Showing results (331-340 of 351) with videos related to

Sort By:
Pageof 36
Cancers|July 9, 2022
Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk StratificationTong-Yoon Kim, Silvia Park, Daehun Kwag, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromesJae-Ho Yoon, Young-Woo Jeon, Seung-Ah Yahng, et al.
Annals of Hematology|October 12, 2012
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangementHee-Jin Kim, Hee Kyung Ahn, Chul Won Jung, et al.
Bone Marrow Transplantation|March 4, 2024
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1Silvia Park, Su-Yeon Bang, Daehun Kwag, et al.
Annals of Hematology|November 6, 2015
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplantJae-Sook Ahn, Jae-Young Kim, Hyeoung-Joon Kim, et al.
Hematology (Amsterdam, Netherlands)|May 21, 2013
Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitorsSung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, et al.
Therapeutic Advances in Hematology|March 28, 2022
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)Silvia Park, Daehun Kwag, Tong Yoon Kim, et al.
Cancers|September 23, 2022
Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic PatientsTong-Yoon Kim, Daehun Kwag, Jong-Hyuk Lee, et al.
Bone Marrow Transplantation|September 23, 2022
Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemiaGa-Young Song, TaeHyung Kim, Seo-Yeon Ahn, et al.
Blood|June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trialStéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Pageof 36